Dr. Fred Sancilio reports

LOBE SCIENCES ANNOUNCES $341,425 CAD PRIVATE PLACEMENT FOR GENERAL CORPORATE PURPOSES

Lobe Sciences Ltd. has arranged a non-brokered private placement of up to 8,535,625 common shares of the company at a price of four cents per share for gross proceeds of up to $341,425.

The net proceeds of the offering will be used for general corporate purposes, including working capital and continuing operational needs.

All securities to be issued pursuant to the offering will be subject to a statutory four-month-and-one-day hold period.

About Lobe Sciences Ltd.

Lobe Sciences is a growth-stage biopharmaceutical company developing advanced treatments for rare and neurologically underserved conditions. Through its wholly owned subsidiary Altemia Inc. and majority-owned Cynaptec Pharmaceuticals Inc. Lobe is advancing a patented lipid-based delivery platform for the treatment of sickle cell disease and a proprietary oral analogue of psilocin-conjugated psilocin -- targeted for chronic cluster headache and related disorders. The company's mission is to improve patient outcomes through innovation and precision-driven science.

We seek Safe Harbor.